AN INDIRECT TREATMENT COMPARISON AND COST-EFFECTIVENESS ANALYSIS COMPARING FOLFIRINOX WITH NAB-PACLITAXEL PLUS GEMCITABINE FOR FIRST-LINE TREATMENT FOR PATIENTS WITH METASTATIC PANCREATIC CANCER

被引：4
|
作者：
Hollmann, S. [1 ]
Alloul, K. [2 ]
Attard, C. [1 ]
Kavan, P. [3 ]
机构：
[1] Cornerstone Res Grp, Burlington, ON, Canada
[2] Sanofi Canada, Laval, PQ, Canada
[3] McGill Univ, Jewish Gen Hosp, Segal Canc Ctr E 715, Montreal, PQ H3T 1E2, Canada
来源：
ANNALS OF ONCOLOGY | 2014年 / 25卷
关键词：
D O I：
10.1093/annonc/mdu164.18
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD - 0018
引用
收藏
页码：11 / 11
页数：1
相关论文
共 50 条
  • [21] Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting
    Braiteh, Fadi
    Patel, Manish B.
    Parisi, Monika
    Ni, Quanhong
    Park, Siyeon
    Faria, Claudio
    CANCER MANAGEMENT AND RESEARCH, 2017, 9 : 141 - 148
  • [22] First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population
    Hatashima, Alycia
    Arango, Matthew J.
    Reardon, Joshua
    Freeman, Tracelyn
    Williams, Terence
    McLaughlin, Eric M.
    Abushahin, Laith
    FUTURE ONCOLOGY, 2022, 18 (20) : 2521 - 2532
  • [23] Second-line treatment of modified FOLFIRINOX or nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma
    Ozaka, Masato
    Sasaki, Takashi
    Yamada, Ikuhiro
    Kanata, Ryo
    Akiyama, Dai
    Katagiri, Tomoko
    Takano, Koichi
    Matsuyama, Masato
    Sasahira, Naoki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [24] Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis
    Riedl, Jakob M.
    Posch, Florian
    Horvath, Lena
    Gantschnigg, Antonia
    Renneberg, Felix
    Schwarzenbacher, Esther
    Moik, Florian
    Barth, Dominik A.
    Rossmann, Christopher H.
    Stotz, Michael
    Schaberl-Moser, Renate
    Pichler, Martin
    Stoger, Herbert
    Greil, Richard
    Djanani, Angela
    Schlick, Konstantin
    Gerger, Armin
    EUROPEAN JOURNAL OF CANCER, 2021, 151 : 3 - 13
  • [25] Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer
    Fukahori, Masaru
    Okabe, Yoshinobu
    Shimokawa, Mototsugu
    Otsuka, Taiga
    Koga, Futa
    Ueda, Yujiro
    Nakazawa, Junichi
    Komori, Azusa
    Otsu, Satoshi
    Arima, Shiho
    Makiyama, Akitaka
    Taguchi, Hiroki
    Honda, Takuya
    Ushijima, Tomoyuki
    Miwa, Keisuke
    Shibuki, Taro
    Nio, Kenta
    Ide, Yasushi
    Ureshino, Norio
    Mizuta, Toshihiko
    Mitsugi, Kenji
    Shirakawa, Tsuyoshi
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [26] Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer
    Masaru Fukahori
    Yoshinobu Okabe
    Mototsugu Shimokawa
    Taiga Otsuka
    Futa Koga
    Yujiro Ueda
    Junichi Nakazawa
    Azusa Komori
    Satoshi Otsu
    Shiho Arima
    Akitaka Makiyama
    Hiroki Taguchi
    Takuya Honda
    Tomoyuki Ushijima
    Keisuke Miwa
    Taro Shibuki
    Kenta Nio
    Yasushi Ide
    Norio Ureshino
    Toshihiko Mizuta
    Kenji Mitsugi
    Tsuyoshi Shirakawa
    Scientific Reports, 13
  • [27] Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer.
    Attard, Cheryl L.
    Brown, Stephen
    Alloul, Karine
    Moore, Malcolm J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [28] Efficacy and toxicity comparison of nab-paclitaxel plus S-1 and nab-paclitaxel plus gemcitabine as first-line chemotherapy for metastatic pancreatic cancer
    Guo Xi
    Xu Yaolin
    Ji Yuan
    Fan Yue
    Wang Dansong
    Jin Dayong
    Zhuang Rongyuan
    Wu Lili
    Lou Wenhui
    Zhou Yuhong
    Department of Medical Oncology
    Department of General Surgery
    Department of Pathology
    Department of Traditional Chinese Medicine
    Department of Radiotherapy
    胰腺病学杂志（英文）, 2020, 03 (01) : 35 - 41
  • [29] Safety and efficacy of first-line gemcitabine plus nab-paclitaxel for elderly metastatic pancreatic cancer patients
    Pecora, I.
    Vivaldi, C.
    Rovesti, G.
    Catanese, S.
    Salani, F.
    Gardini, A. Casadei
    Massa, V.
    Bernardini, L.
    Riggi, M.
    Andrikou, K.
    Rapposelli, I.
    Formica, V.
    Cesario, S.
    Caccese, M.
    Lencioni, M.
    Vasile, E.
    Falcone, A.
    Fornaro, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S151 - S151
  • [30] Economic evaluation for the United States (US) of gemcitabine (GEM), nab-paclitaxel plus gemcitabine (NAB-P plus GEM), and FOLFIRINOX as first-line treatment for metastatic pancreatic cancer (MPC)
    Gharaibeh, Mahdi
    McBride, Ali
    Bootman, J. Lyle
    Cranmer, Lee D.
    Abraham, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345